These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 17255299)
1. Update on the application of interleukin-2 in the treatment of renal cell carcinoma. McDermott DF Clin Cancer Res; 2007 Jan; 13(2 Pt 2):716s-720s. PubMed ID: 17255299 [TBL] [Abstract][Full Text] [Related]
5. Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma. Atkins MB; Regan M; McDermott D Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6342S-6S. PubMed ID: 15448028 [TBL] [Abstract][Full Text] [Related]
6. Application of IL-2 and other cytokines in renal cancer. McDermott DF; Atkins MB Expert Opin Biol Ther; 2004 Apr; 4(4):455-68. PubMed ID: 15102596 [TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe. Negrier S; Maral J; Drevon M; Vinke J; Escudier B; Philip T Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S93-8. PubMed ID: 10685667 [TBL] [Abstract][Full Text] [Related]
13. Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with high-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic response. Ridolfi L; de Rosa F; Ridolfi R; Gentili G; Valmorri L; Scarpi E; Parisi E; Romeo A; Guidoboni M J Transl Med; 2014 Sep; 12():262. PubMed ID: 25245327 [TBL] [Abstract][Full Text] [Related]
14. Treatment of metastatic renal cell carcinoma. Reeves DJ; Liu CY Cancer Chemother Pharmacol; 2009 Jun; 64(1):11-25. PubMed ID: 19343348 [TBL] [Abstract][Full Text] [Related]
15. Contemporary trends in high-dose interleukin-2 use for metastatic renal cell carcinoma in the United States. Allard CB; Gelpi-Hammerschmidt F; Harshman LC; Choueiri TK; Faiena I; Modi P; Chung BI; Tinay I; Singer EA; Chang SL Urol Oncol; 2015 Nov; 33(11):496.e11-6. PubMed ID: 26210683 [TBL] [Abstract][Full Text] [Related]
16. Predicting response to interleukin-2 therapy among patients with renal cell carcinoma. Leppert JT; Lam JS; Belldegrun AS J Immunother; 2005; 28(5):427-9. PubMed ID: 16113598 [No Abstract] [Full Text] [Related]
17. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma. Weiss GR; Margolin KA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Gaynor ER; Boldt DH; Doroshow JH; Bar MH J Clin Oncol; 1992 Feb; 10(2):275-81. PubMed ID: 1732429 [TBL] [Abstract][Full Text] [Related]
18. Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-alpha in patients with progressive metastatic renal cell carcinoma. Verra N; Jansen R; Groenewegen G; Mallo H; Kersten MJ; Bex A; Vyth-Dreese FA; Sein J; van de Kasteele W; Nooijen WJ; de Waal M; Horenblas S; de Gast GC Br J Cancer; 2003 May; 88(9):1346-51. PubMed ID: 12778059 [TBL] [Abstract][Full Text] [Related]
19. [Cytokine therapy for metastatic renal cell carcinoma]. Eto M; Naito S Gan To Kagaku Ryoho; 2002 Oct; 29(10):1738-44. PubMed ID: 12402423 [TBL] [Abstract][Full Text] [Related]
20. Rational selection of a control arm for randomised trials in metastatic renal cell carcinoma. Mickisch GH Eur Urol; 2003 Jun; 43(6):670-9. PubMed ID: 12767369 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]